Harry Bartelink, professor in Clinical Experimental Radiotherapy of the University of Amsterdam, is chairman of the Radiotherapy Division at The Netherlands Cancer Institute in Amsterdam, responsible for patient care and scientific research with particular interest in breast cancer and image guided intensity modulated radiotherapy.

His scientific activities include measurements of growth and regression rate of human tumours, irradiated with photons or fast neutrons; interaction of radiotherapy and chemotherapy in patients with lung, breast and head and neck cancer; predictive assays indicating possible adaptation of fractionation schedules; high dose-high precision radiotherapy; image processing and quality assurance. Recently his attention has been focused on the prediction of treatment outcome with micro-arrays in breast cancer patients. He currently holds various honorary positions: honorary fellow of the American College of Radiology, ESTRO Breur Medallist and the GH Fletcher Award. He is also a member of the Board of several European organizations, President of FECS, Past-President of ESTRO.

He holds membership of several editorial boards: International Journal of Radiation, Oncology, Biology and Physics, Radiotherapy & Oncology, European Journal of Cancer, The Breast, Journal of Oncology, The Cancer Journal of Scientific American, The Oncologist. From 1990 to 1994, he was joint editor in chief of the Radiotherapy & Oncology journal. At present, his is author of more than 160 publications.